Logo image of GBT

GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Fundamental Analysis

USA - NASDAQ:GBT - US37890U1088 - Common Stock

68.49 USD
+0.01 (+0.01%)
Last: 10/4/2022, 8:00:01 PM
68.49 USD
0 (0%)
After Hours: 10/4/2022, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, GBT scores 2 out of 10 in our fundamental rating. GBT was compared to 538 industry peers in the Biotechnology industry. GBT may be in some trouble as it scores bad on both profitability and health. GBT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GBT has reported negative net income.
GBT Yearly Net Income VS EBIT VS OCF VS FCFGBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -37.05%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GBT Yearly ROA, ROE, ROICGBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

Industry RankSector Rank
OM -127.41%
PM (TTM) -137.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBT Yearly Profit, Operating, Gross MarginsGBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

GBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
GBT has more shares outstanding than it did 1 year ago.
The debt/assets ratio for GBT is higher compared to a year ago.
GBT Yearly Shares OutstandingGBT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
GBT Yearly Total Debt VS Total AssetsGBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.24, we must say that GBT is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 4.92 is on the high side and indicates that GBT has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF N/A
Altman-Z 1.24
ROIC/WACCN/A
WACC10.15%
GBT Yearly LT Debt VS Equity VS FCFGBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.88 indicates that GBT has no problem at all paying its short term obligations.
A Quick Ratio of 6.17 indicates that GBT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.17
GBT Yearly Current Assets VS Current LiabilitesGBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for GBT have decreased strongly by -16.51% in the last year.
The Revenue has grown by 42.53% in the past year. This is a very strong growth!
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%50.46%

3.2 Future

Based on estimates for the next years, GBT will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.02% on average per year.
GBT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.11% yearly.
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%

3.3 Evolution

GBT Yearly Revenue VS EstimatesGBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
GBT Yearly EPS VS EstimatesGBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBT. In the last year negative earnings were reported.
Also next year GBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBT Price Earnings VS Forward Price EarningsGBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -15.98
GBT Per share dataGBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

GBT's earnings are expected to grow with 21.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y21.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLOBAL BLOOD THERAPEUTICS IN

NASDAQ:GBT (10/4/2022, 8:00:01 PM)

After market: 68.49 0 (0%)

68.49

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2022-08-08/bmo
Earnings (Next)11-03 2022-11-03/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.93%
Ins Owner Change0%
Market Cap4.62B
Analysts68.18
Price Target67.97 (-0.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.68
P/FCF N/A
P/OCF N/A
P/B 39.05
P/tB N/A
EV/EBITDA -15.98
EPS(TTM)-5.01
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.48
BVpS1.75
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -127.41%
PM (TTM) -137.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.17
Altman-Z 1.24
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%50.46%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A